Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters

The emergence of SARS-CoV-2 in December 2019 resulted in the COVID-19 pandemic. Recurring disease outbreaks repeatedly overloaded the public health sector and severely affected the global economy. We developed a candidate COVID-19 vaccine based on a recombinant Newcastle disease virus (NDV) vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: de Swart, Rik L., de Leeuw, Olav S., Oreshkova, Nadia, Gerhards, Nora M., Albulescu, Irina C., Vreman, Sandra, Gonzales, José L., Maas, Riks, van Kuppeveld, Frank J.M., Soema, Peter, Bosch, Berend-Jan, Peeters, Ben P.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257146/
https://www.ncbi.nlm.nih.gov/pubmed/35820941
http://dx.doi.org/10.1016/j.vaccine.2022.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257146/
https://www.ncbi.nlm.nih.gov/pubmed/35820941
http://dx.doi.org/10.1016/j.vaccine.2022.07.005

Ejemplares similares